Malignant Perivascular Epithelioid Cell Neoplasms Approved for Marketing Phase Trials for Sirolimus (DB00877)

Also known as: Malignant PEComa (Perivascular Epithelioid Cell Tumors) / PEComa, Malignant / Malignant PEComa / Malignant PEComa (perivascular epithelioid cell tumor) / Malignant perivascular epithelioid cell neoplasm / Malignant perivascular epithelioid cell neoplasm (disorder) / Perivascular epithelioid tumor, malignant (morphologic abnormality)

DBCOND0144087 (Malignant Perivascular Epithelioid Cell Neoplasms)Approved for MarketingNot Available IdentifierTitlePurposeDrugs
NCT03817515Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation